MUMBAI, June 27 (Reuters) - India's Ranbaxy Laboratories rose 5.8 percent in early trading after the U.S. Food and Drug Administration said on Thursday it had approved the company's generic version of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results